KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Maria Debiec-RychterAustralasian GastroIntestinal Trials Group

Abstract

A recent randomized EORTC phase III trial, comparing two doses of imatinib in patients with advanced gastrointestinal stromal tumours (GISTs), reported dose dependency for progression-free survival. The current analysis of that study aimed to assess if tumour mutational status correlates with clinical response to imatinib. Pre-treatment samples of GISTs from 377 patients enrolled in phase III study were analyzed for mutations of KIT or PDGFRA by combination of D-HPLC and direct sequencing of tumour genomic DNA. Mutation types were correlated with patients' survival data. The presence of exon 9-activating mutations in KIT was the strongest adverse prognostic factor for response to imatinib, increasing the relative risk of progression by 171% (P<0.0001) and the relative risk of death by 190% (P<0.0001) when compared with KIT exon 11 mutants. Similarly, the relative risk of progression was increased by 108% (P<0.0001) and the relative risk of death by 76% (P=0.028) in patients without detectable KIT or PDGFRA mutations. In patients whose tumours expressed an exon 9 KIT oncoprotein, treatment with the high-dose regimen resulted in a significantly superior progression-free survival (P=0.0013), with a reduction of the relative risk o...Continue Reading

References

Mar 7, 2000·The American Journal of Pathology·M L LuxJ A Fletcher
Nov 14, 2001·Lancet·A T van OosteromUNKNOWN European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Aug 16, 2002·The New England Journal of Medicine·George D DemetriHeikki Joensuu
Nov 9, 2002·The Lancet Oncology·Heikki JoensuuGeorge Demetri
Dec 4, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael C HeinrichJonathan A Fletcher
Mar 11, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M Debiec-RychterUNKNOWN EORTC Soft Tissue and Bone Sarcoma Group
Sep 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher L CorlessMichael C Heinrich
Aug 16, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·John R ZalcbergUNKNOWN Australasian Gastrointestinal Trials Group

❮ Previous
Next ❯

Citations

Dec 24, 2005·Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen·P Hohenberger, E Wardelmann
Sep 30, 2009·Der Radiologe·H-U SchildhausE Wardelmann
Jul 1, 2011·Archives of Toxicology·Eirini Thanopoulou, Ian Judson
Dec 27, 2011·Cancer Immunology, Immunotherapy : CII·Lei L ChenRobert S Benjamin
Dec 1, 2010·Cancer Chemotherapy and Pharmacology·Francine Aubin, Charles D Blanke
Dec 25, 2010·Cancer Chemotherapy and Pharmacology·Wei-Lien WangJonathan C Trent
Dec 1, 2010·Cancer Chemotherapy and Pharmacology·Mrinal M Gounder, Robert G Maki
Dec 9, 2010·Cancer Chemotherapy and Pharmacology·Suzanne George, Jonathan C Trent
Aug 13, 2013·Cancer Chemotherapy and Pharmacology·Peter ReichardtJean-Yves Blay
Sep 13, 2012·Der Pathologe·E Wardelmann
Nov 30, 2011·International Journal of Colorectal Disease·Alexander W BehamB Michael Ghadimi
Sep 30, 2009·Virchows Archiv : an International Journal of Pathology·Judith V M G Bovée, Pancras C W Hogendoorn
Jan 5, 2010·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Toshirou NishidaYasuaki Miyazaki
Aug 22, 2009·Wiener medizinische Wochenschrift·Ferdinand PlonerUNKNOWN für das österreichische GIST-Panel
Mar 20, 2013·Wiener medizinische Wochenschrift·Evelyne BareckUNKNOWN Austrian representatives of Medical and Surgical Oncology, Pathology, Radiology, Nuclear Medicine, Gastroenterology, and Lab
Jan 30, 2010·Cancer Metastasis Reviews·Georgios S Papaetis, Kostas N Syrigos
Apr 4, 2009·Targeted Oncology·Florence Duffaud, Axel Le Cesne
Apr 3, 2010·Targeted Oncology·Philippe A Cassier, Jean-Yves Blay
Jul 4, 2012·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Ronald P Dematteo
Jun 26, 2007·Current Oncology Reports·Alexander J F LazarDina Lev
Sep 10, 2008·Current Oncology Reports·Peter Reichardt
Dec 5, 2009·Journal of Gastrointestinal Cancer·Juan Manuel Sanchez HidalgoJavier Briceño Delgado
Jan 25, 2011·Medical Oncology·Margherita NanniniMaria Abbondanza Pantaleo
Jul 10, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Blanca Homet MorenoRicardo Hitt
Oct 16, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Javier Martín-BrotoJosé Antonio López-Guerrero
Dec 3, 2013·Indian Journal of Surgical Oncology·M R Sreevathsa
Jun 19, 2013·Trends in Molecular Medicine·Yihai Cao
Apr 30, 2013·Lancet·Heikki JoensuuChristopher L Corless
Feb 5, 2008·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Jerzy LasotaMarkku Miettinen
Jun 24, 2008·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Cristina R Antonescu
Sep 1, 2009·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Carlos A Torres-CabalaDoina Ivan
May 19, 2009·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Jerzy LasotaMarkku Miettinen
Apr 20, 2013·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Sebastian HussHans-Ulrich Schildhaus
Nov 3, 2006·Nature Clinical Practice. Oncology·Michael C Heinrich, Christopher L Corless

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.